Debating clinical utility

Wylie Burke, A. M. Laberge, Nancy Press

    Research output: Contribution to journalArticle

    43 Citations (Scopus)

    Abstract

    The clinical utility of genetic tests is determined by the outcomes following test use. Like other measures of value, it is often contested. Stakeholders may have different views about benefits and risks and about the importance of social versus health outcomes. They also commonly disagree about the evidence needed to determine whether a test is effective in achieving a specific outcome. Questions may be presented as factual disagreements, when they are actually debates about what information matters or how facts should be interpreted and used in clinical decision-making. Defining the different issues at stake is therefore an important element of policy-making. Key issues include evidence standards for test use, and in particular, the circumstances under which prospective controlled data should be required, as well as evidence on feasibility, cost and equitable delivery of testing; the goals of population-based screening programs, and in particular, the role of social outcomes in evaluating test value; and the appropriate uses and funding of tests that inform non-medical actions. Addressing each of these issues requires attention to stakeholder values and methods for effective deliberation that incorporate consumer as well as health professional perspectives.

    Original languageEnglish (US)
    Pages (from-to)215-223
    Number of pages9
    JournalPublic Health Genomics
    Volume13
    Issue number4
    DOIs
    StatePublished - Apr 2010

    Fingerprint

    Policy Making
    Health
    Costs and Cost Analysis
    Population
    Clinical Decision-Making

    Keywords

    • Clinical utility
    • Evidence-based practice
    • Genetic testing

    ASJC Scopus subject areas

    • Genetics(clinical)
    • Public Health, Environmental and Occupational Health

    Cite this

    Debating clinical utility. / Burke, Wylie; Laberge, A. M.; Press, Nancy.

    In: Public Health Genomics, Vol. 13, No. 4, 04.2010, p. 215-223.

    Research output: Contribution to journalArticle

    Burke, W, Laberge, AM & Press, N 2010, 'Debating clinical utility', Public Health Genomics, vol. 13, no. 4, pp. 215-223. https://doi.org/10.1159/000279623
    Burke, Wylie ; Laberge, A. M. ; Press, Nancy. / Debating clinical utility. In: Public Health Genomics. 2010 ; Vol. 13, No. 4. pp. 215-223.
    @article{2f70152385c2432eb12079af611a6433,
    title = "Debating clinical utility",
    abstract = "The clinical utility of genetic tests is determined by the outcomes following test use. Like other measures of value, it is often contested. Stakeholders may have different views about benefits and risks and about the importance of social versus health outcomes. They also commonly disagree about the evidence needed to determine whether a test is effective in achieving a specific outcome. Questions may be presented as factual disagreements, when they are actually debates about what information matters or how facts should be interpreted and used in clinical decision-making. Defining the different issues at stake is therefore an important element of policy-making. Key issues include evidence standards for test use, and in particular, the circumstances under which prospective controlled data should be required, as well as evidence on feasibility, cost and equitable delivery of testing; the goals of population-based screening programs, and in particular, the role of social outcomes in evaluating test value; and the appropriate uses and funding of tests that inform non-medical actions. Addressing each of these issues requires attention to stakeholder values and methods for effective deliberation that incorporate consumer as well as health professional perspectives.",
    keywords = "Clinical utility, Evidence-based practice, Genetic testing",
    author = "Wylie Burke and Laberge, {A. M.} and Nancy Press",
    year = "2010",
    month = "4",
    doi = "10.1159/000279623",
    language = "English (US)",
    volume = "13",
    pages = "215--223",
    journal = "Public Health Genomics",
    issn = "1662-4246",
    publisher = "S. Karger AG",
    number = "4",

    }

    TY - JOUR

    T1 - Debating clinical utility

    AU - Burke, Wylie

    AU - Laberge, A. M.

    AU - Press, Nancy

    PY - 2010/4

    Y1 - 2010/4

    N2 - The clinical utility of genetic tests is determined by the outcomes following test use. Like other measures of value, it is often contested. Stakeholders may have different views about benefits and risks and about the importance of social versus health outcomes. They also commonly disagree about the evidence needed to determine whether a test is effective in achieving a specific outcome. Questions may be presented as factual disagreements, when they are actually debates about what information matters or how facts should be interpreted and used in clinical decision-making. Defining the different issues at stake is therefore an important element of policy-making. Key issues include evidence standards for test use, and in particular, the circumstances under which prospective controlled data should be required, as well as evidence on feasibility, cost and equitable delivery of testing; the goals of population-based screening programs, and in particular, the role of social outcomes in evaluating test value; and the appropriate uses and funding of tests that inform non-medical actions. Addressing each of these issues requires attention to stakeholder values and methods for effective deliberation that incorporate consumer as well as health professional perspectives.

    AB - The clinical utility of genetic tests is determined by the outcomes following test use. Like other measures of value, it is often contested. Stakeholders may have different views about benefits and risks and about the importance of social versus health outcomes. They also commonly disagree about the evidence needed to determine whether a test is effective in achieving a specific outcome. Questions may be presented as factual disagreements, when they are actually debates about what information matters or how facts should be interpreted and used in clinical decision-making. Defining the different issues at stake is therefore an important element of policy-making. Key issues include evidence standards for test use, and in particular, the circumstances under which prospective controlled data should be required, as well as evidence on feasibility, cost and equitable delivery of testing; the goals of population-based screening programs, and in particular, the role of social outcomes in evaluating test value; and the appropriate uses and funding of tests that inform non-medical actions. Addressing each of these issues requires attention to stakeholder values and methods for effective deliberation that incorporate consumer as well as health professional perspectives.

    KW - Clinical utility

    KW - Evidence-based practice

    KW - Genetic testing

    UR - http://www.scopus.com/inward/record.url?scp=77951469552&partnerID=8YFLogxK

    UR - http://www.scopus.com/inward/citedby.url?scp=77951469552&partnerID=8YFLogxK

    U2 - 10.1159/000279623

    DO - 10.1159/000279623

    M3 - Article

    VL - 13

    SP - 215

    EP - 223

    JO - Public Health Genomics

    JF - Public Health Genomics

    SN - 1662-4246

    IS - 4

    ER -